| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLFN11 |
| Uniprot No | Q7Z7L1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 345-901aa |
| 氨基酸序列 | EKWVGMMTDTDPDLLQLSEDFECQLSLSSGPPLSRPVYSKKGLEHKKELQQLLFSVPPGYLRYTPESLWRDLISEHRGLEELINKQMQPFFRGILIFSRSWAVDLNLQEKPGVICDALLIAQNSTPILYTILREQDAEGQDYCTRTAFTLKQKLVNMGGYTGKVCVRAKVLCLSPESSAEALEAAVSPMDYPASYSLAGTQHMEALLQSLVIVLLGFRSLLSDQLGCEVLNLLTAQQYEIFSRSLRKNRELFVHGLPGSGKTIMAMKIMEKIRNVFHCEAHRILYVCENQPLRNFISDRNICRAETRKTFLRENFEHIQHIVIDEAQNFRTEDGDWYGKAKSITRRAKGGPGILWIFLDYFQTSHLDCSGLPPLSDQYPREELTRIVRNADPIAKYLQKEMQVIRSNPSFNIPTGCLEVFPEAEWSQGVQGTLRIKKYLTVEQIMTCVADTCRRFFDRGYSPKDVAVLVSTAKEVEHYKYELLKAMRKKRVVQLSDACDMLGDHIVLDSVRRFSGLERSIVFGIHPRTADPAILPNVLICLASRAKQHLYIFPWGGH |
| 预测分子量 | 69.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLFN11重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **《SLFN11 blocks stressed replication forks independently of ATR》**
- **作者**: Muñoz, I.M., et al.
- **摘要**: 该研究通过重组SLFN11蛋白的体外实验，揭示了其直接结合并抑制停滞的DNA复制叉的功能。研究证明，SLFN11通过切割染色质结合的RNA分子破坏复制叉的稳定性，且这一过程不依赖ATR信号通路，为SLFN11在化疗敏感性中的作用提供了分子机制解释。
2. **《Schlafen 11 (SLFN11) is a dominant determinant of sensitivity to DNA-targeted agents》**
- **作者**: Zoppoli, G., et al.
- **摘要**: 文章发现SLFN11表达水平与癌细胞对DNA损伤药物(如铂类、拓扑异构酶抑制剂)的敏感性密切相关。通过重组蛋白功能实验，研究者验证了SLFN11通过干扰DNA修复途径增强药物杀伤效果，并建议将其作为预测化疗反应的生物标志物。
3. **《Structural and functional analysis of the Schlafen11 C-terminal domain》**
- **作者**: Li, Y., et al.
- **摘要**: 该研究利用重组SLFN11蛋白的C端结构域进行结构解析(X射线晶体学)，揭示了其独特的核酸酶活性位点。实验表明该结构域对单链DNA/RNA具有特异性切割能力，为SLFN11在抗肿瘤中的作用提供了结构基础。
---
这些文献分别从功能机制、临床相关性及结构生物学角度研究了SLFN11重组蛋白的作用，涵盖其在DNA损伤修复、化疗敏感性及酶活性方面的关键发现。
**Background of SLFN11 Recombinant Protein**
Schlafen family member 11 (SLFN11) is a protein encoded by the *SLFN11* gene, belonging to the Schlafen family known for roles in cell proliferation, differentiation, and immune modulation. SLFN11 has gained attention for its critical function in the cellular response to DNA damage and replication stress. It acts as a determinant of sensitivity to DNA-targeting anticancer therapies, including PARP inhibitors, platinum-based agents, and topoisomerase inhibitors.
Structurally, SLFN11 contains an N-terminal AAA ATPase domain and a C-terminal helicase-like domain, though its enzymatic activity remains under investigation. It selectively binds stressed replication forks, inhibits checkpoint maintenance, and promotes irreversible cell cycle arrest or apoptosis. SLFN11 is also implicated in regulating ribosomal RNA (rRNA) processing and translation, potentially disrupting protein synthesis in stressed cells.
Recombinant SLFN11 protein is engineered for *in vitro* and *in vivo* studies to dissect its molecular mechanisms. Produced via expression systems (e.g., *E. coli* or mammalian cells), it retains functional domains for binding nucleic acids or interacting with replication/translation machinery. Research using recombinant SLFN11 has clarified its role in sensitizing cancer cells to genotoxic agents, highlighting its potential as a biomarker for predicting chemotherapy response.
SLFN11 expression is epigenetically regulated and frequently silenced in cancers, correlating with therapy resistance. Its recombinant form aids in restoring function or testing combinatorial therapies. Furthermore, studies explore SLFN11's interplay with immune signaling, suggesting broader implications in oncology and immunotherapy.
In summary, SLFN11 recombinant protein serves as a vital tool for unraveling its tumor-suppressive mechanisms and advancing precision medicine strategies in cancer treatment.
×
